In the meta-analysis of 3 studies 20,28,32 which compared a GLP-1-based therapy against a comparator, GLP-1-based therapies were found to increase % FMD non-significantly (mean difference [95% CI] in the changes from baseline: 1.65 [0.89, 4.18] %
Spoiler alert: dont waste your money
GLP #2 has also demonstrated success over the long term
By targeting the GLP-1, GIP, and glucagon receptors simultaneously, retatrutide works with your bodys natural signals to reduce hunger, stabilize blood sugar, and rev up your metabolism
Aim for at least 1200 calories daily for women and 1500 for men, even when appetite is low
No clinical trial has tested the retatrutide+cagrilintide combination as of May 2026